Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

Servier will be responsible for development and global commercialisation of the therapy for several indications.

According to studies approximately 15% of cancers are caused by viruses. Read more to know about the viruses that cause ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with bes ...

French independent pharma firm Servier and USA-based Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will ...

A new research collaboration is applying fundamental expertise in cellular biology with commercial technology to explore how ...

Merger Completion: On August 15, 2024, Silexion completed its business combination with Moringa Acquisition Corp, becoming a publicly traded company on Nasdaq under the ticker “SLXN.” This strategic ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...

Anocca has secured authorisation from regulatory authorities in four European nations for its Phase I/II VIDAR-1 clinical ...